STOCK TITAN

Renalytix Plc - RNLX STOCK NEWS

Welcome to our dedicated news page for Renalytix Plc (Ticker: RNLX), a resource for investors and traders seeking the latest updates and insights on Renalytix Plc.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Renalytix Plc's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Renalytix Plc's position in the market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.34%
Tags
management
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.6%
Tags
none
-
Rhea-AI Summary
Renalytix plc (NASDAQ: RNLX) (LSE: RENX) announced clinical data demonstrating that KidneyIntelX in vitro prognostic testing led to improvements in both type 2 diabetes and chronic kidney disease health through 12 months. The results are from a real-world evidence study in New York City, with 2,317 patients. Median A1C levels improved by 0.7% in high-risk patients, and median eGFR slope improved from -7.1 to 4.5ml/min/1.73m2 in high-risk patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.15%
Tags
none
Rhea-AI Summary
Renalytix announces the appointment of Catherine Coste to the Board of Directors. Coste brings extensive financial experience and will help maintain financial and risk compliance as Renalytix expands distribution for its FDA approved KidneyIntelX test.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.82%
Tags
management
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
41.06%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.72%
Tags
conferences
Rhea-AI Summary
Renalytix Reports Financial Results for Q3 2023, Highlights FDA Progress and Insurance Coverage Contracts
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.34%
Tags
earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.98%
Tags
conferences earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.46%
Tags
none
Renalytix Plc

Nasdaq:RNLX

RNLX Rankings

RNLX Stock Data

55.23M
71.45M
4.66%
8.64%
1%
Diagnostic Imaging Centers
Health Care and Social Assistance
Link
United Kingdom
Penarth

About RNLX

renalytix ai plc (lse aim: renx) is a leading developer of artificial intelligence-enabled clinical diagnostic solutions for kidney disease, one of the most common and costly chronic medical conditions globally. the company’s solutions are being designed to make significant improvements in kidney disease diagnosis and prognosis, clinical care, patient stratification for drug clinical trials, and drug target discovery. renalytixai’s initial diagnostic product, kidneyintelx™, is designed to diagnose and improve clinical management of patients with type ii diabetes and those of african ancestry with fast-progressing kidney disease in an effort to curtail the estimated $114 billion cost of chronic and end-stage kidney disease to the u.s. healthcare system. renalytixai expects to commercially launch kidneyintelx as a laboratory developed test in its clia laboratory facilities to health systems and drug developers in h2 2019. the company also intends to submit kidneyintelx for regulatory rev